Regeneron Pharmaceuticals, Inc. (FRA:RGO)
Germany · Delayed Price · Currency is EUR | Market Cap | 86.89B +44.0% |
| Revenue (ttm) | 14.88B +18.6% |
| Net Income | 4.24B +5.2% |
| EPS | 40.97 +8.6% |
| Shares Out | n/a |
| PE Ratio | 21.15 |
| Forward PE | 11.39 |
| Dividend | 3.27 (0.38%) |
| Ex-Dividend Date | Nov 20, 2026 |
| Volume | 66 |
| Open | 853.80 |
| Previous Close | 859.10 |
| Day's Range | 853.80 - 866.70 |
| 52-Week Range | 507.90 - 868.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron’s baloncibart reduces orthostatic heart rate in Phase 2 trial
Regeneron (REGN) announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome, or POTS, evaluating baloncibart, a novel, investigational, first-in-class m...
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked in...
Alnylam says Regeneron advances CIDEBsiRNA with FIH results in MASLD patients
Alnylam Pharmaceuticals (ALNY) announced that its collaborator, Regeneron Pharmaceuticals (REGN), shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CID...
Regeneron Pharmaceuticals Transcript: Investor update
The Genetics Center has enabled nearly 50 target discoveries or validations, with six programs in the clinic. CIDEB siRNA cut liver fat by up to 80% in early data and is advancing into registrational-intent studies, amid a projected $15B-plus U.S. MASH market by 2035.
Regeneron Pharmaceuticals Slides: Investor update
Regeneron Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Regeneron announces results from trial of CIDEBsiRNA
Regeneron (REGN) Pharmaceuticals announced the first results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA rapidly normalized liver fat and improved liver inju...
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD
Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in Londo...
Regeneron price target raised to $913 from $810 at RBC Capital
RBC Capital raised the firm’s price target on Regeneron (REGN) to $913 from $810 and keeps a Sector Perform rating on the shares. The company’s strong commercial quarter underscores the…
Regeneron price target raised to $997 from $835 at Leerink
Leerink analyst David Risinger raised the firm’s price target on Regeneron (REGN) to $997 from $835 and keeps a Market Perform rating on the shares following significant Q3 results upside.
Regeneron price target raised to $982 from $780 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Regeneron (REGN) to $982 from $780 and keeps a Buy rating on the shares. The company posted strong top- and…
Regeneron price target raised to $980 from $795 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Regeneron (REGN) to $980 from $795 and keeps an Overweight rating on the shares. The firm sees “something closer to ~$80/share” in…
Regeneron price target raised to $1,100 from $1,030 at Guggenheim
Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,100 from $1,030 and keeps a Buy rating on the shares.
Regeneron price target raised to $1,175 from $922 at Canaccord
Canaccord raised the firm’s price target on Regeneron (REGN) to $1,175 from $922 and keeps a Buy rating on the shares. The firm said Dupixent’s impressive beat vs consensus reaffirms…
Regeneron price target raised to $875 from $761 at Baird
Baird analyst Brian Skorney raised the firm’s price target on Regeneron (REGN) to $875 from $761 and keeps a Neutral rating on the shares. The firm updated its model following…
Regeneron price target raised to $812 from $756 at Bernstein
Bernstein raised the firm’s price target on Regeneron (REGN) to $812 from $756 and keeps a Market Perform rating on the shares. The firm notes Regeneron delivered a strong Q3…
Regeneron price target raised to $925 from $750 at Wells Fargo
Wells Fargo raised the firm’s price target on Regeneron (REGN) to $925 from $750 and keeps an Equal Weight rating on the shares. The firm cites the company’s strong commercial…
Regeneron price target raised to $1,030 from $908 at BofA
BofA raised the firm’s price target on Regeneron (REGN) to $1,030 from $908 and keeps a Buy rating on the shares. The company reported solid Q3 results across key products,…
Regeneron price target raised to $855 from $779 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $855 from $779 and keeps an Equal Weight rating on the shares. The firm views the…
Regeneron price target raised to $1,000 from $865 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Regeneron (REGN) to $1,000 from $865 and keeps an Overweight rating on the shares.
Regeneron price target raised to $1,050 from $950 at JPMorgan
JPMorgan raised the firm’s price target on Regeneron (REGN) to $1,050 from $950 and keeps an Overweight rating on the shares after the company reported a meaningful Q3 beat, driven…
Regeneron price target raised to $1,020 from $911 at Raymond James
Raymond James raised the firm’s price target on Regeneron (REGN) to $1,020 from $911 and keeps an Outperform rating on the shares. The firm raised its price target following a…
Regeneron price target raised to $825 from $740 at Citi
Citi raised the firm’s price target on Regeneron (REGN) to $825 from $740 and keeps a Neutral rating on the shares. The firm upped Regeneron’s estimates post the better than…
Regeneron Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 36% and non-GAAP EPS 70%, with record sales for DUPIXENT, EYLEA HD, and LIBTAYO. Investment in a broad pipeline is set to accelerate, while 2027 R&D expense is expected to rise at a mid-teens rate.